A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against <i>Mycobacterium tuberculosis</i>
<b>Background/Objectives.</b> Tuberculosis is a deadly bacterial disease and the second most common cause of death from monoinfectious diseases worldwide. Comprehensive measures taken by health authorities in various countries in recent decades have saved tens of millions of lives, but t...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/11/1267 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850147059265437696 |
|---|---|
| author | Alena Kozlova Ildus Pateev Galina Shepelkova Olga Vasileva Natalia Zakharova Vladimir Yeremeev Roman Ivanov Vasiliy Reshetnikov |
| author_facet | Alena Kozlova Ildus Pateev Galina Shepelkova Olga Vasileva Natalia Zakharova Vladimir Yeremeev Roman Ivanov Vasiliy Reshetnikov |
| author_sort | Alena Kozlova |
| collection | DOAJ |
| description | <b>Background/Objectives.</b> Tuberculosis is a deadly bacterial disease and the second most common cause of death from monoinfectious diseases worldwide. Comprehensive measures taken by health authorities in various countries in recent decades have saved tens of millions of lives, but the number of new cases of this infection has been steadily increasing in the last few years and already exceeds 10 million new cases annually. The development of new vaccines against tuberculosis is a priority area in the prevention of new cases of the disease. mRNA vaccines have already shown high efficacy against COVID-19 and other viral infections and can currently be considered a promising field of antituberculosis vaccination. In our previous study, we assessed the immunogenicity and protective activity of several types of antituberculosis mRNA vaccines with different 5′ untranslated regions, but the efficacy of these vaccines was either comparable with or lower than that of BCG. <b>Methods.</b> Here, we conducted a comprehensive experiment to investigate the effects of cotranscriptional capping conditions and of cap structure on the magnitude of the mRNAs’ translation in HEK293T and DC2.4 cells. The most effective cap version was used to create an antituberculosis mRNA vaccine called mEpitope-ESAT6. <b>Results and Conclusions</b>. We compared immunogenicity and protective activity between mEpitope-ESAT6 and BCG and found that the vaccine with the new cap type is more immunogenic than BCG. Nonetheless, the increased immunogenicity did not enhance vaccine-induced protection. Thus, the incorporation of different cap analogs into mRNA allows to modulate the efficacy of mRNA vaccines. |
| format | Article |
| id | doaj-art-c6cd6495d65d4e0fab1b13a25e99af57 |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-c6cd6495d65d4e0fab1b13a25e99af572025-08-20T02:27:41ZengMDPI AGVaccines2076-393X2024-11-011211126710.3390/vaccines12111267A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against <i>Mycobacterium tuberculosis</i>Alena Kozlova0Ildus Pateev1Galina Shepelkova2Olga Vasileva3Natalia Zakharova4Vladimir Yeremeev5Roman Ivanov6Vasiliy Reshetnikov7Translational Medicine Research Center, Sirius University of Science and Technology, Sochi 354340, RussiaTranslational Medicine Research Center, Sirius University of Science and Technology, Sochi 354340, RussiaCentral Tuberculosis Research Institute, Moscow 107564, RussiaTranslational Medicine Research Center, Sirius University of Science and Technology, Sochi 354340, RussiaTranslational Medicine Research Center, Sirius University of Science and Technology, Sochi 354340, RussiaCentral Tuberculosis Research Institute, Moscow 107564, RussiaTranslational Medicine Research Center, Sirius University of Science and Technology, Sochi 354340, RussiaTranslational Medicine Research Center, Sirius University of Science and Technology, Sochi 354340, Russia<b>Background/Objectives.</b> Tuberculosis is a deadly bacterial disease and the second most common cause of death from monoinfectious diseases worldwide. Comprehensive measures taken by health authorities in various countries in recent decades have saved tens of millions of lives, but the number of new cases of this infection has been steadily increasing in the last few years and already exceeds 10 million new cases annually. The development of new vaccines against tuberculosis is a priority area in the prevention of new cases of the disease. mRNA vaccines have already shown high efficacy against COVID-19 and other viral infections and can currently be considered a promising field of antituberculosis vaccination. In our previous study, we assessed the immunogenicity and protective activity of several types of antituberculosis mRNA vaccines with different 5′ untranslated regions, but the efficacy of these vaccines was either comparable with or lower than that of BCG. <b>Methods.</b> Here, we conducted a comprehensive experiment to investigate the effects of cotranscriptional capping conditions and of cap structure on the magnitude of the mRNAs’ translation in HEK293T and DC2.4 cells. The most effective cap version was used to create an antituberculosis mRNA vaccine called mEpitope-ESAT6. <b>Results and Conclusions</b>. We compared immunogenicity and protective activity between mEpitope-ESAT6 and BCG and found that the vaccine with the new cap type is more immunogenic than BCG. Nonetheless, the increased immunogenicity did not enhance vaccine-induced protection. Thus, the incorporation of different cap analogs into mRNA allows to modulate the efficacy of mRNA vaccines.https://www.mdpi.com/2076-393X/12/11/1267RNA vaccinecap analogtuberculosisadaptive immunityprotective immunity |
| spellingShingle | Alena Kozlova Ildus Pateev Galina Shepelkova Olga Vasileva Natalia Zakharova Vladimir Yeremeev Roman Ivanov Vasiliy Reshetnikov A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against <i>Mycobacterium tuberculosis</i> Vaccines RNA vaccine cap analog tuberculosis adaptive immunity protective immunity |
| title | A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against <i>Mycobacterium tuberculosis</i> |
| title_full | A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against <i>Mycobacterium tuberculosis</i> |
| title_fullStr | A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against <i>Mycobacterium tuberculosis</i> |
| title_full_unstemmed | A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against <i>Mycobacterium tuberculosis</i> |
| title_short | A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against <i>Mycobacterium tuberculosis</i> |
| title_sort | cap optimized mrna encoding multiepitope antigen esat6 induces robust cellular and humoral immune responses against i mycobacterium tuberculosis i |
| topic | RNA vaccine cap analog tuberculosis adaptive immunity protective immunity |
| url | https://www.mdpi.com/2076-393X/12/11/1267 |
| work_keys_str_mv | AT alenakozlova acapoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT ilduspateev acapoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT galinashepelkova acapoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT olgavasileva acapoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT nataliazakharova acapoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT vladimiryeremeev acapoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT romanivanov acapoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT vasiliyreshetnikov acapoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT alenakozlova capoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT ilduspateev capoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT galinashepelkova capoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT olgavasileva capoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT nataliazakharova capoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT vladimiryeremeev capoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT romanivanov capoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi AT vasiliyreshetnikov capoptimizedmrnaencodingmultiepitopeantigenesat6inducesrobustcellularandhumoralimmuneresponsesagainstimycobacteriumtuberculosisi |